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Abstract
Objective: GH insensitivity (GHI) is caused in the majority of cases by impaired function of the GH
receptor (GHR). All but one known GHR mutation are in the coding sequence or the exon/intron
boundaries. We identiﬁed and characterised the ﬁrst intronic defect occurring in the polypyrimidine
tract of the GHR in a patient with severe GHI.
Design: We investigated the effect of the novel defect on mRNA splicing using an in vitro splicing assay
and a cell transfection system.
Methods: GHR was analysed by direct sequencing. To assess the effect of the novel defect, two
heterologous minigenes (wild-type and mutant L1-GHR8-L2) were generated by inserting GHR exon 8
and its ﬂanking wild-type or mutant intronic sequences into a well-characterised splicing reporter
(Adml-par L1–L2).
32P-labelled pre-mRNA was generated from the two constructs and incubated in
HeLa nuclear extracts or HEK293 cells.
Results: Sequencing of the GHR revealed a novel homozygous defect in the polypyrimidine tract of
intron 7 (IVS7-6TOA). This base change does not involve the highly conserved splice site sequences,
and is not predicted in silico to affect GHR mRNA splicing. Nevertheless, skipping of exon 8 from the
mutant L1-GHR8-L2 mRNA was clearly demonstrated in the in vitro splicing assay and in transfected
HEK293 cells.
Conclusion: Disruption of the GHR polypyrimidine tract causes aberrant mRNA splicing leading to a
mutant GHR protein. This is predicted to lack its transmembrane and intracellular domains and, thus,
be incapable of transducing a GH signal.
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Introduction
Primary GH insensitivity (GHI) is a rare inherited
disorder characterised by severe postnatal growth
failure, normal or increased GH secretion and insulin-
like growth factor 1 (IGF1) deﬁciency. In the majority of
GHI patients, a genetic defect in the GH receptor (GHR)
gene leading to a functionless receptor is present (1).
Approximately 20% of these defects alter the
mechanism by which GHR coding exons are deﬁned
and correctly assembled to form the mature mRNA (2),
a process known as mRNA splicing (3).
Defects affecting the efﬁciency of mRNA splicing
comprise one-half of DNA point mutations responsible
for human genetic disease (3, 4). The majority of splice
mutations disrupt the native splice site through a base
change within the invariant donor or acceptor dinu-
cleotides (5). Mutations within other splice elements,
such as the polypyrimidine tract and the branch point,
may also cause genetic diseases through the exclusion
of a constitutive exon from the mature mRNA (6), but
these are less frequent.
The vast majority of GHR splice defects identiﬁed so
far disrupt the invariant dinucleotide at the splice sites
leading to aberrant mRNA splicing and a mutant GHR
protein. We report the ﬁrst mutation identiﬁed in the
polypyrimidine tract of the GHR causing aberrant GHR
mRNA splicing and GHI.
Materials and methods
Molecular analysis
A patient was referred for severe short stature. Informed
consent for genetic analysis was obtained from his
parents, and approval was obtained from the local
ethics committee.
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leucocytes.GHRcodingexons,includingthepseudoexon
6J, and their intronic boundaries were ampliﬁed by
PCR using speciﬁc primers (primer sequences available
onrequest).PCRproductswerevisualisedon1%agarose
gel and were sequenced using the ABI Prism Big Dye
Sequencing kit and the ABI 3700 automated DNA
sequencer (Applied Biosystems, Warrington, UK) in
accordance with the manufacturer’s instructions.
Creation of minigenes
The wild-type minigene L1-GHR8-L2 was created by
inserting the GHR exon 8 and its intronic boundaries
between exons L1 and L2 of a well-characterised splice
reporter Adml-par (7). The GHR exon 8 and 89 bp of its
ﬂanking introns were ampliﬁed from human genomic
DNA, and exons L1 and L2 were ampliﬁed from Adml-
par by PCR using speciﬁc primers (sequences available
on request). The three exons were joined together by
overlap extension PCR (8). Adml-par was ampliﬁed
using primers T7-L1 and L2A (T7L1: 50 TAATACGACT-
CACTATAGGGAGACCGGCAGATCAGCTT 30,L 2 A :
50 ATCCAAGAGTACTGGAAAGACCG 30) and was used
as a positive control for the splicing reaction. PCR
products were run on a 1% agarose gel and those
corresponding in size to the three-exon minigene were
cut and puriﬁed by PCR gel extraction. The identity of
the PCR product was conﬁrmed by direct sequencing
on the ABI 3700 sequencer. PCR products were cloned
in the pGEM T-easy vector system (Promega), and the
presence of the insert was assessed by direct sequencing
of plasmid DNA. The mutant L1-GHR8-L2 minigene
was obtained by site-directed mutagenesis using speciﬁc
primers (sequences available on request) and the
wild-type minigene as a template.
RNA preparation
Wild-type and mutant DNA minigenes and Adml-par
weretranscribedintoRNAinthepresenceof[
32P-a]GTP.
Transcription reactions contained 200 ng DNA, 1 ml
10! transcription buffer (Ambion, Warrington, UK),
1 ml NTPs (5 mmol ATP, CTP and UTP), 10 mCi [
32P-a]
GTP (Perkin-Elmer, Massachusetts, USA), RNA CAP and
20 U/ml T7 RNA polymerase Plus (Ambion) in a ﬁnal
volume of 10 ml. Reactions mixtures were incubated for
1 h at 37 8C, run on a 4% polyacrylamide gel and gel
puriﬁed. RNA was eluted from the gel (elution buffer:
0.5 Msodiumacetate,pH5.2,1 mMEDTAand0.2%SDS),
ethanol precipitated and resuspended in RNAse-free H2O.
In vitro splicing assay
A splice reaction mixture containing 20 fmol RNA, 8 ml
HeLa nuclear extracts (CilBiotech, s.a., Mons, Belgium),
1 ml2 5 ! ATP/CP (12.5 mM ATP and 0.5 M creatine
phosphate), 1 ml 80 mM MgCl2,5 ml 13% polyvinyl
alcohol, 1.25 ml 0.4 M Hepes-KOH (pH 7.3), 7 ml Buffer
D (20 mM Hepes-KOH, pH 8.0, 100 mM KCl, 0.2 mM
EDTA, 20% glycerol, 0.5 mM phenylmethylsulphonyl
ﬂuoride and 1 mM dithiothreitol) in 25 ml ﬁnal volume
was incubated at 30 8C for 1 h. Control reaction
mixtures were kept on ice for the same time. At the
end of the incubation, reaction mixtures were deprotei-
nised, precipitated and run on an 8% denaturing
polyacrylamide gel before autoradiography. The bands
of interest, corresponding in size to correctly spliced
or aberrant products, were excised from the gel and
retro-transcribed into cDNA. This was ampliﬁed by
RT-PCR using primers T7L1 and L2A and products
analysed by direct sequencing on the ABI 3700
DNA sequencer.
Cell transfection and RT-PCR
Wild-type and mutant minigenes L1-GHR8-L2 were
subcloned from the bacterial pGEM T-easy vector into
the mammalian pcDNA 3.1 vector. The identity and
correct orientation of the pcDNA3.1 L1-GHR8-L2
insert were assessed by direct sequencing on the ABI
3700 sequencer. HEK293 cells were maintained in
DMEM (Sigma–Aldrich) with 10% foetal bovine serum
(Sigma–Aldrich) at 37 8C under 5% CO2 and split
when conﬂuent. Before transfection, HEK293 cells
were seeded into a six-well plate. Cells were transiently
transfected when w70% conﬂuent with the wild-type
or mutant pcDNA3.1 L1-GHR8-L2 plasmid (50 ng)
using Lipofectamine 2000 (Invitrogen). Forty-eight
hours after transfection, cells were harvested, and
RNA was extracted and reverse transcribed into
cDNA. cDNA was ampliﬁed in the presence of
0.5 mCi [
32P-a] dCTP with primers T7L1 and L2A in
a 12.5 ml PCR mixture. PCR products were electro-
phoresed on an 8% non-denaturating polyacrylamide
gel prior to autoradiography and quantitation on a
PhosphorImager (Molecular Dynamics Ltd, Chesham,
Bucks, UK). The percentage of alternative splicing was
calculated as the ratio of isoform/total of all isoforms,
and results are presented as meanGS.D. of at least
three separate experiments.
Hormone assay
Serum IGF1, IGF-binding protein 3 (IGFBP3), acid-labile
subunit (ALS) and GH-binding protein (GHBP) were
measured from venous blood samples using enzyme-
linked immunosorbent assays (ELISA kit; Diagnostic
System Laboratories, Inc., Webster, TX, USA). For IGF1,
the assay sensitivity was 0.03 ng/ml. The intra- and
inter-assay coefﬁcients of variation (CV) were 8.6 and
6.8% for mean serum concentrations of 104 and
90 ng/ml respectively. For IGFBP3, assay sensitivity
was 0.04 ng/ml. Mean intra- and inter-assay CV were
7.2 and 8.3% respectively. Serum GHBP was measured
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ﬁltration method (9). GHBP is given as a percentage of
speciﬁc binding, calculated as the difference between
total binding and non-speciﬁc binding.
In silico analysis
The novel nucleotide change was studied using the Alex
Dong Li’s splice site ﬁnder (http://violin.genet.sickkids.
on.ca/wali/splicesiteﬁnder.html), which is an in silico
prediction program that calculates the scores of donor,
acceptor and branch sequences using an algorithm
based on that created by Shapiro & Senapathy (10).
Results
Biochemical and auxological data
A 1.5-year-old boy of Bangladeshi origin from a
consanguineous marriage was referred for severe
short stature (K6.0 SDS for age and sex). He had facial
features typical of Laron syndrome, with a prominent
forehead and a depressed nasal bridge. Biochemical data
showed low IGF1Z30 ng/ml (n.r. 8–141 ng/ml) and
IGFBP3Z0.35 mg/l (n.r. 1.1–3.8 mg/l). GH levels were
markedly elevated at baseline, which were equal to
1145 mUI/l and after stimulation test with glucagon
were equal to 1195 mUI/l. Serum GHBP levels were
29% (normal range 15–20%). His parents’ heights
were K1.58 SDS (father) and K1.55 SDS (mother).
Genetic analysis
Sequencing of GHR revealed the presence of a
homozygous T to A base change six bases upstream
the acceptor splice site of intron 7 (IVS7-6TOA). In
both parents, the same mutation was present in
heterozygosity (Fig. 1). No other mutations were
found in the GHR coding sequence, intronic boundaries
and pseudoexon 6J.
The T to A intronic defect does not abolish the
GHR intron 7 acceptor splice site in silico
The thymine located six bases upstream the acceptor
splice site of intron 7 is a conserved nucleotide (www.
ensembl.org). The T to A base change was predicted,
in silico,tocauseamodest reductionof intron 7 acceptor
splice site score (wild-type 85.57 versus mutant 82.80).
The T to A intronic defect causes GHR exon 8
skipping in vitro
The wild-type minigene L1-GHRexon8-L2 and the
corresponding mutant were created to study the
nucleotide change IVS7-6TOA, which is located in
the polypyrimidine tract before exon 8 and tested with
the in vitro splicing assay. After 1 h under standard
splicing conditions, the wild-type minigene produced a
band of 277nt corresponding to the three-exon
correctly spliced product L1-GHRexon8-L2 (54G2%
of exon 8 inclusion) alongside a 186nt band corre-
sponding to L1–L2 mRNA, the identity of which was
conﬁrmed by direct sequencing. The TOA mutation
resulted in the complete skippingof GHRexon 8 and the
appearance of the 186nt band, corresponding to exons
L1 and L2 joined together, as conﬁrmed by direct
sequencing. No band of 277nt corresponding to
L1-GHRexon8-L2 was present among the mutant
minigene splice products (Fig. 2).
The T to A intronic defect causes GHR exon 8
skipping in HEK293 cells
In order to conﬁrm the effect of the T to A mutation on
mRNA splicing, the wild-type minigene L1-GHRexon8-
L2 and the corresponding mutant were subcloned in
the mammalian pcDNA3.1 vector and transfected
into HEK293 cells. After 48 h, the wild-type minigene
produced a band of 277nt, corresponding to
L1-GHRexon8-L2, alongside the 186nt band corre-
sponding toL1–L2. TheIVS7-6TtoAmutation resulted,
instead, in the complete skipping of GHR exon 8 and the
appearance of the 186nt band, corresponding to exons
L1 and L2 joined together, as conﬁrmed by direct
sequencing (Fig. 3).
Figure 1 GHR polypyrimidine tract. (A) Schematic representation of
the typical eukaryotic intronic nucleotide sequence upstream the
intron/exon splice junction (top) and the nucleotide composition
of the intronic region upstream GHR exon 8 (bottom). Pyrimidines
are shown in uppercase letters; position and length of the
polypyrimidine tract (Poly-Y) are also indicated. (B) IVS7-6TOA.
Chromatograms showing partial DNA sequences for the patient,
his parents and a normal control are presented. The position of
the mutation is indicated by the arrows. Y, pyrimidines; n, any
nucleotide.
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This study describes the ﬁrst mutation within the
polypyrimidine tract of the GHR in a patient with GHI.
This homozygous defect causes aberrant mRNA
splicing, resulting in the skipping of GHR exon 8 and
a prematurely truncated GHR protein.
Approximately 20% of GHR defects causing GHI are
splice mutations (2). All defects disrupt the invariant
splice site sequences, with rare exceptions involving the
activation of cryptic intronic (11) or exonic splice sites
(12). The splicing process involves the recognition of
splice elements by a ribonucleoprotein complex called
the spliceosome (13). The polypyrimidine tract is an
intronic sequence rich in pyrimidines (14–16).I ti s
located upstream of the acceptor splice site, and has
been shown to be involved in the initial stages of
spliceosome binding to the mRNA (17). Mutational
studies have demonstrated that the length and location
of the polypyrimidine sequence can affect spliceosome
apposition and, thus, splicing efﬁciency (18).
The intronic base change identiﬁed and characterised
in this study is located upstream of the acceptor splice
site of GHR intron 7 in the polypyrimidine tract.
Mutations within this splice element are known to
contribute to genetic diseases by inducing the exclusion
of a constitutive exon or inclusion of an alternative one
in the mature mRNA (5, 19). Nevertheless, mutations
in the polypyrimidine tract are a rare ﬁnding, possibly
because of the difﬁculty in predicting their deleterious
effect. In silico prediction programs are, in fact, fairly
reliable when used to predict the effects of nucleotide
changes occurring at the invariant donor and acceptor
dinucleotide sequences, but become less efﬁcient as
nucleotide changes occur further away from the splice
sites or in different splicing elements, such as the
polypyrimidine tract (20).
The TOA nucleotide substitution identiﬁed in
homozygosity in this GHI patient and in heterozygosity
in his parents shortens the polypyrimidine tract of GHR
intron 7. In silico analysis did not predict the abolition of
the acceptor splice site, but only a modest reduction in
its score, whose signiﬁcance was unclear. As mRNA
from the patient was not available, the effect of this
novel GHR intronic nucleotide change was investigated
by comparing mRNA splicing of the mutant and the
wild-type minigenes in HeLa nuclear extract and in
HEK293 cells. A clear GHR exon skipping was
demonstrated for the mutant mRNA in both systems.
The thymine substitution is likely to affect GHR splicing
by interfering with the binding of the U2AF spliceosome
element to the GHR mRNA. The resulting mutant GHR
transcript will lack exon 8, with exon 7 splicing into
exon 9, as was the case for the exon 8 splice site
mutation described by Woods et al., which led to an
exon 8-lacking mutant GHR (21). The skipping of exon
8 causes a frameshift and the appearance of a
premature stop codon.
The presence of circulating GHBP in our patient is
evidence that the mutant GHR is expressed. Moreover,
elevated GHBP levels suggest that the aberrant splicing
caused by the polypyrimidine tract defect and docu-
mented in the in vitro experiment also occurs in vivo.
GHBP is the product of the cleavage of the GHR
Figure 3 Effects of the GHR T to A nucleotide change on mRNA splicing in HEK293 cells. (A) Radioactive RT-PCR analysis performed with
mRNA fromHEK293cells transfectedwiththe wild-typeor mutantminigeneL1-GHRexon8-L2.Thestructureofthe correct(L1-Ex8-L2)and
aberrant (L1–L2) splice products and their expected sizes are indicated. (B) Schematic representation of the splice events for the wild-type
and mutant minigenes. Mutation location is indicated by an asterisk.
Figure 2 Results for the in vitro splicing assay. The wild-type (Wt)
and mutant (Mt) minigenes L1-GHRexon8-L2 and Adml-par were
incubated in HeLa nuclear extracts for 60 min at 30 8C. Control
reaction mixtures were incubated at 0 8C. The structures of the
pre-mRNA and the mRNA splice products are indicated next to
the autoradiogram. The expected size of the splice products is
also indicated. Bands corresponding to correct and aberrant
mRNA splice products are indicated by the arrows.
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The prematurely truncated receptor lacks its trans-
membrane and intracellular domains and would be
unable to signal or be anchored in the cell membrane,
thus explaining the elevated GHBP levels seen in our
patient, as well as in previously described cases of
mutant GHR arising from exon 8 splice site defects (21,
23). The characteristics of the GHBP arising from this
mutant GHR were described by Woods et al., who
demonstrated a normal GH binding afﬁnity and a
molecular weight similar to that of normal controls
(21). Analysis of GHBP characteristics in our patient
would be expected to produce similar results and was,
thus, not performed.
It is of interest that although the truncated mutant
GHR is not able to signal, the patient had detectable
IGF1 levels, albeit very low, especially in relation to the
extremely elevated GH levels. The production of small
amounts of IGF1 in patients with exon 8-lacking GHR
has alsobeendocumentedbyotherauthors(22).Infact,
splice defects may not always be 100% efﬁcient in
causing aberrant splicing (24–26), and very low
amounts of wild-type GHR may be produced and could
beresponsible for thelowIGF1levelsseeninour patient.
The patient’s parents, heterozygous carriers of the
polypyrimidine tract defect, are likely to express the
mutant GHR. Although no mRNA was available from
the parents of our patient, other authors have
demonstrated the presence of mRNA for the exon
8-lacking mutant receptor in heterozygous carriers of
exon 8 splice mutations (21). The polypyrimidine tract
defect did not cause short stature or Laron features in
heterozygosity, as was true for other exon 8-skipping
mutations (23). However, elevated GHBP levels have
been described in heterozygous carriers (23) and may be
present in the parents of our patient, but could not
be demonstrated as blood was not available.
GHR exon 8 skipping was observed in the presence of
the wild-type polypyrimidine tract in both in vitro and
cellular studies. It could be postulated that the GHR
exon 8 splice site is constitutively weak, and that
the shortening of its polypyrimidine tract, as in the
presence of the novel T to A nucleotide change, favours
its skipping.
In conclusion, we have described a novel rare cause of
GHI resulting from the alteration of the GHR polypyr-
imidine tract. This nucleotide change, located outside
the invariant splice site, was not predicted to abolish
GHR splicing in silico, but was clearly shown in vitro to
induce skipping of GHR exon 8. This strengthens the
concept that the search for gene mutations should
include careful analysis of non-coding sequences and, in
particular, of intronic splice elements.
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